Adnan Ayhanci

Adnan Ayhanci

Auto-generated profile, based on publicly available information

Adnan Ayhanci

Eskisehir Osmangazi University

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2009 in Biological Trace Element Research
Verified
Journal Article
Open access
PDF file
AAAdnan Ayhanci
Adnan Ayhanci
SGSibel Günes
Sibel Günes
VSVarol Sahinturk
Varol Sahinturk
SASila Appak-Baskoy
Sila Appak-Baskoy
RURuhi Uyar
Ruhi Uyar
SYSuzan Yaman
Suzan Yaman
The anticancer drug cyclophosphamide (CP) has nephrotoxic effects besides its urotoxicity, which both in turn limit its clinical utility. The nephrotoxicity of CP is less common compared to its urotoxicity, and not much importance has been given for the study of mechanism of CP-induced nephrotoxicity so far. Overproduction of reactive oxygen species (ROS) during inflammation is one of the reasons of the kidney injury. Selenoproteins play crucial roles in regulating ROS and redox status in nearly all tissues; therefore, in this study, the nephrotoxicity of CP and the possible protective effects of seleno l-methionine (SLM) on rat kidneys were investigated. Forty-two Sprague–Dawley rats were equally divided into six groups of seven rats each. The control group received saline, and other rats were injected with CP (100 mg/kg), SLM (0.5 or 1 mg/kg), or CP + SLM intraperitoneally. Malondialdehyde (MDA) and glutathione (GSH) levels in kidney homogenates of rats were measured, and kidney tissues were examined under the microscope. CP-treated rats showed a depletion of renal GSH levels (28% of control), while CP + SLM-injected rats had GSH values close to the control group. MDA levels increased 36% of control following CP administration, which were significantly decreased after SLM treatment. Furthermore, these biochemical results were supported by microscopical observations. In conclusion, the present study not only points to the therapeutic potential of SLM in CP-induced kidney toxicity but also indicates a significant role for ROS and their relation to kidney dysfunction.

6 October 2016 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
SGSibel Gunes
Sibel Gunes
VSVarol Sahinturk
Varol Sahinturk
PKPinar Karasati
Pinar Karasati
ISIlknur Kulcanay Sahin
Ilknur Kulcanay Sahin
AAAdnan Ayhanci
Adnan Ayhanci

16 November 2019 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
AAAdnan Ayhanci
Adnan Ayhanci
DTDondu Tugce Tanriverdi
Dondu Tugce Tanriverdi
VSVarol Sahinturk
Varol Sahinturk
MCMustafa Cengiz
Mustafa Cengiz
SASila Appak-Baskoy
Sila Appak-Baskoy
ISIlknur Kulcanay Sahin
Ilknur Kulcanay Sahin

19 July 2008 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
AAAdnan Ayhanci
Adnan Ayhanci
RURuhi Uyar
Ruhi Uyar
EAErinc Aral
Erinc Aral
SKSelda Kabadere
Selda Kabadere
SASila Appak-Baskoy
Sila Appak-Baskoy

28 May 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
SYSongul CETIK YILDIZ
Songul CETIK YILDIZ
CDCemil Demir
Cemil Demir
Mustafa CengizMustafa Cengiz
Mustafa Cengiz
HIHalit IRMAK
Halit IRMAK
BPBetul C. Peker
Betul C. Peker
AAAdnan Ayhanci
Adnan Ayhanci
Fermented prebiotic and probiotic products with kefir are very important to slow down and prevent the growth of tumors and to treat cancer by stimulating the immune response against tumor cells. Cyclophosphamide (CPx) is widely preferred in cancer treatment but its effectiveness in high doses is restricted because of its side effects. The aim of this study was to investigate the protective effects of kefir against CPx-induced heart and liver toxicity. In an experiment, 42 Wistar albino rats were divided into six treatment groups: the control (Group 1), the group receiving 150 mg/kg CPx (Group 2), the groups receiving 5 and 10 mg/kg kefir (Groups 3 and 4) and the groups receiving 5 and 10 mg/kg kefir + CPx (Group 5 and 6). Fermented kefirs obtained on different days by traditional methods were mixed and given by gavage for 12 days, while a single dose of CPx was administered intraperitoneally (i.p.) on the 12th day of the experiment. It was observed that alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), creatinine kinase-MB (CK-MB), ischemia modified albumin (IMA) and Troponin I values, which indicate oxidative stress, increased in the CPx-administered group, and this level approached that of the control in the CPx + kefir groups. Likewise, as a result of the kefir, the rats’ CPx-induced histopathological symptoms were reduced, and their heart and liver tissue were significantly improved. In conclusion, it was observed that kefir had a cytoprotective effect against CPx-induced oxidative stress, hepatotoxicity and cardiotoxicity, bringing their biochemical parameters closer to those of the control by suppressing oxidative stress and reducing tissue damage.

1 October 2009 in Drug and Chemical Toxicology
Verified
Journal Article
Open access
AAAdnan Ayhanci
Adnan Ayhanci
SYSuzan Yaman
Suzan Yaman
SASila Appak-Baskoy
Sila Appak-Baskoy
SGSibel Gunes
Sibel Gunes
Cyclophosphamide (CP) is a widely used antineoplastic drug that causes toxicity in the normal cell due to its metabolites. The major drawback of this drug is an undesirable myelosuppression. Selenium (Se) is a potent nutritional antioxidant that carries out biological effects by its incorporation into selenoproteins, such as glutathione peroxidase (GPx). The possible protective effects of seleno-L-methionine (SLM) against CP-related toxicity of blood cells and bone marrow of rats were investigated in this study. Intraperitoneal (i.p) administration of 50, 100, or 150 mg/kg of CP caused, in a dose-dependent manner, reductions in the number of leukocytes (78, 89, and 92%, respectively), thrombocytes (22, 33, and 52%, respectively), and bone marrow-nucleated cells (72, 90, and 94%, respectively). The groups that had CP treatment alone were killed 3 days after the CP injection. For the groups having CP+SLM, SLM (0.4 or 0.8 mg/kg i.p) administration was started 3 days earlier than the CP administration and continued to the end of the experiment (6 days). On day 4, the animals were weighed again, relative doses of CP were estimated, and CP+SLM was administered together. On day 7, blood samples were collected and bone marrow of animals were resected under anesthesia. The results indicated that treatment of rats within a select dose range of SLM could reduce CP-induced toxicity on blood cells and bone marrow.